Quality Chemical Industries Limited (QCIL) has announced an interim dividend for the financial year ending March 31, 2026, after successfully recovering a long-outstanding receivable from the Government of the Republic of Zambia.
In a notice issued under Rule 41 of the Uganda Securities Exchange Listing Rules 2025, the company said its Board of Directors, at a meeting held on February 4, 2026, resolved to declare an interim dividend of Shs6 per share.
The dividend will be paid on or before March 5, 2026, to shareholders whose names appear on the company’s share register at the close of business on February 26, 2026.
It will be subject to withholding tax, depending on the shareholder’s domicile.
QCIL noted that the declaration follows the full recovery of the previously impaired receivable from Zambia.
“With this collection now complete, the matter is considered fully resolved,” the company said.
The company said the payout was guided by its dividend policy, the one-off nature of the Zambia recovery, projected full-year performance, and funding commitments.
However, QCIL cautioned that the interim dividend should not be taken as a benchmark for future distributions.
“Shareholders should note that this interim dividend does not set a precedent for future distributions. QCIL remains in a growth and investment phase, with ongoing capital requirements to support manufacturing capacity, product development and market expansion,” the notice reads.
The Board thanked shareholders for their patience during the recovery process.
“The Board thanks shareholders for their patience and continued support during the recovery of the GoZ receivable. We remain steadfast in our commitment to delivering value to our shareholders while navigating the challenges and opportunities in our operating environment,” it added.
Quality Chemical Industries Limited is one of Uganda’s leading pharmaceutical manufacturers, producing a range of essential medicines and health products for local and regional markets.
Listed on the Uganda Securities Exchange, the company has positioned itself as a key player in improving access to affordable medicines in East Africa.
The interim dividend announcement signals improved cash flow and a positive milestone as QCIL continues to invest in growth and expansion.
